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ABSTRACT 
Human Leucocyte antigen (HLA) C*06:02 is identified as the allele associated with the highest 
risk for the development of the autoimmune skin disease psoriasis. However, the diversity and 
mode of peptide presentation by the HLA-C*06:02 molecule remains unclear. Here, we describe 
the endogenous peptide repertoire of approximately 3,000 sequences for HLA-C*06:02 that 
defines the peptide-binding motif for this HLA allomorph. We found that HLA-C*06:02 
predominantly presents nonamer peptides with dominant arginine anchors at the P2 & P7 
positions and a preference for small hydrophobic residues at the C-terminus (PΩ). To determine 
the structural basis of this selectivity, we determined crystal structures of HLA-C*06:02 in 
complex with two self-peptides (ARTELYRSL and ARFNDLRFV) and an analogue of a 
melanocyte auto-antigen (ADAMTSL5, VRSRR-abu-LRL) implicated in psoriasis. These 
structures revealed that HLA-C*06:02 possesses a deep peptide-binding groove comprising two 
electronegative B- and E-pockets that coincide with the preference for P2 and P7 arginine 
anchors. The ADAMTSL5 autoantigen possessed a P7-Leu instead of the P7-Arg residue, but 
nevertheless was accommodated within the HLA-C*06:02 antigen-binding cleft. Collectively, 
our results provide the structural basis for understanding peptide repertoire selection in HLA-
C*06:02. 
 
INTRODUCTION 
The Major Histocompatibility Complex (MHC) class I locus (human leukocyte antigen (HLA)-I 
in humans) encodes highly polymorphic molecules that present antigenic peptides to both the 
adaptive and the innate arms of the immune system. Expressed on all nucleated cells, HLA-I 
present peptides derived from the cytosolic turnover of proteins that are surveyed by αβ T-cell 
receptors on cytotoxic T-cells to monitor for metabolic or pathogenic transformation. 
Complementing this system, natural killer cells (NK) express inhibitory Killer-cell 
immunoglobulin-like receptors (KIR) that monitor for HLA-I expression, thereby ensuring that 
immune surveillance cannot be subverted via down-regulation of HLA-I (1, 2). The polymorphic 
sites within HLA-I molecules are generally clustered within the peptide-binding groove 
facilitating the presentation of diverse peptide repertoires within individuals and across the 
population (3–6). The breadth in HLA-I diversity can result in idiosyncratic HLA-associated 
pathologies like drug hypersensitivities and autoimmune disorders. For example, abacavir 
hypersensitivity is associated with HLA-B*57:01 (7), Birdshot Retinochoroidopathy with HLA-
A*29:02 (8), Ankylosing Spondylitis with HLA-B*27:05 (9), and psoriasis with HLA-C*06:02 
(10)
. Autoimmune disorders are typically multifactorial; as such the identification of specific 
autoantigens has been difficult. Nonetheless, progress has been made identifying insulin epitopes 
in diabetes (11, 12) and in the setting of CD4+T-cell recognition of specific autoantigenic epitopes 
presented by HLA-II molecules. For example, the presentation of citrullinated self-epitopes by 
HLA-DRB1*04:01/04 in rheumatoid arthritis (13, 14) and the presentation of deamidated peptides 
derived from dietary gluten by HLA-DQ8 and HLA-DQ2 in celiac disease (15–17). However, 
although the genetic associations are often compelling, the molecular “triggers” and autoantigens 
for many HLA-I-associated autoimmune disorders have remained elusive. 
 
In comparison to the HLA-A an HLA-B allomorphs, HLA-C is relatively under-represented in 
terms of available peptide repertoire and structural data. The current data suggests that HLA-C 
presents a more restricted repertoire of peptides and has a strong preference for nonamers (18–20). 
However, as Rasmussen et al. (18) have noted these generalizations are based on limited data as 
HLA-C represents <3% of the peptide repertoire data in the Immune Epitope Database (21). 
Similarly, in the Protein Data Bank there are only five peptide-HLA-C structures currently 
deposited (22). This disparity is partly attributable to studies on T-cell recognition tending to focus 
on HLA-A and HLA-B that are expressed on the cell surface at 3–10-fold higher levels than 
HLA-C (23, 24). Furthermore, studies into HLA-C have centered on it being primarily a ligand for 
the lineage III KIR on NK cells (1). Therefore, whereas there is an emerging appreciation of the 
role of HLA-C in T-cell-mediated events in viral immunity and psoriasis (reviewed in Ref. 25), 
there remains a paucity of peptide repertoire and structural information. 
 
Psoriasis has a complex genetic component with more than 20 regions of risk identified by 
genome-wide association studies. Of these, psoriasis susceptibility locus 1 (PSORS1) has the 
highest risk association and maps to the region of HLA-C (26). More than 60% of psoriasis 
patients carry the HLA-C*06:02 allele that is linked with early onset of the disease, 
with C*06:02 homozygotes having a 5-fold higher risk association than heterozygotes (27, 28). 
Although tentative associations have been made to the activating lineage III KIR (1, 29–31), 
psoriasis is nonetheless considered a predominantly T-cell-mediated disease that manifests as 
increased proliferation and abnormal differentiation of keratinocytes as well as infiltration of 
inflammatory immune cells into the skin (26, 32–34). Furthermore, environmental factors including 
prior streptococcal infection are linked with disease onset (35). Accordingly, the search for HLA-
C*06:02 restricted autoantigens has focused on skin-related peptides such as those arising from 
the antimicrobial LL-37 peptide (36) and the ADAMTSL5 melanocyte protein (37) as well as 
streptococcal M-protein “molecular mimics” of keratin peptides (38, 39). To date, the identification 
and validation of specific antigenic peptides has been hampered by a lack of structural data on 
the architecture of the HLA-C*06:02 peptide-binding groove and the defining features that drive 
selection of its peptides repertoire. 
 
Here we have utilized high-resolution mass spectrometry to identify native peptides of HLA-
C*06:02 and determined the X-ray crystal structures of C*06:02 in the presence of three self-
peptides including an analogue of a self-peptide derived from the ADAMTSL5 protein (37). Thus, 
we define the HLA-C*06:02 peptide-binding motif and provide the structural basis of peptide 
selection that will assist in the identification and refinement of psoriasis-related autoantigens. 
 
 
RESULTS 
HLA-C*06:02 Peptide Repertoire 
To determine the peptide repertoire and binding motif of HLA-C*06:02, membrane-bound 
complexes (mC*06:02) were expressed on the surface of the HLA class I-deficient B-cell line 
721.221 and peptide complexes purified by immunoaffinity chromatography. Peptides were 
separated by reverse-phase HPLC and identified by high resolution mass spectrometry. For 
mC*06:02 a total of 2142 peptides were identified with the peptides predominantly falling in the 
range of 8–12 amino acids in length (49%) (Fig. 1A). The most abundant peptide length observed 
was nine amino acids with a total of 794 peptides representing 37% of total peptides. Analysis of 
the nonamer peptides revealed three dominant, conserved residues located at the primary anchor 
positions P2 and P9 as well as a potential secondary anchor at P7 (Fig. 1, B and C). For analysis, 
cut-offs for dominant, strong, and preferred amino acids were applied at frequencies of >30, >20, 
and >10%, respectively (as defined previously (40)). At P2, the dominant amino acid was arginine 
(41%) yet tyrosine (9%) and smaller residues such as alanine (12%), glycine (6%), and serine (6%) 
were tolerated. The P7 position also showed a clear bias for arginine (40%) and to a lesser extent 
lysine (12%). The P9 position favored small hydrophobic residues with leucine (40%), valine 
(25%), and isoleucine (12%) appearing as dominant, strong, and preferred residues, respectively. 
The P9 position could also accept larger hydrophobic residues such as tyrosine and methionine, 
however, these occurred at much lower frequencies (9 and 8%, respectively). 
 
The peptide repertoire of a number of HLA-C allomorphs, including HLA-C*06:02, have been 
previously studied by positional scanning combinatorial peptide libraries (PSCPL)  (18). This method 
observed a similar motif for HLA-C*06:02 with preferences for a P2-Arg, a small hydrophobic in 
P9, and a very minor increase in the presence of arginine at P7. The PSCPL screening also indicated 
that HLA-C*07:01 and HLA-C*07:02 have the closest related peptide motif to HLA-C*06:02 with 
P2-Arg and P9 hydrophobic anchor residues. Another study was able to ascertain peptide sequences 
for HLA-C*06:02 from carcinoma cell lines and also showed a similar peptide motif (41). HLA-
C*04:01 is a well-characterized allomorph that has been studied using a similar approach described 
here for HLA-C*06:02 (19). HLA-C*04:01 similarly prefers nonamer peptides and terminal 
hydrophobic anchor residues. The other anchor residues of HLA-C*04:01 are different than HLA-
C*06:02 and it prefers a large hydrophobic at P2-(Phe/Tyr) and has a strong preference for aspartic 
acid at P3 (42).   
 
The peptide repertoire of mC*06:02 also contained peptides ranging from 13 to 23 amino acids in 
length. These peptides did not conform to a standard peptide motif and did not contain any 
significant anchor residues. For example, only 2% of peptides of 16 amino acids in length contain a 
leucine at the terminal position. Therefore, to test the validity of the longer peptides and to confirm 
our motif, we obtained a peptide repertoire of a soluble form of HLA-C*06:02 (sC*06:02). The use 
of soluble HLA-I was aimed at reducing the levels of contaminating peptides from cellular lysis and 
has been used previously to identify naturally processed HLA presented peptides (43–46). 
 
A total of 985 peptides were obtained from sC*06:02. Overall there was a similar length 
distribution to that of mC*06:02. Nonamers were again the most abundant peptide length (37%) 
(Fig. 1A) and showed significant peptide overlap (60%) with mC*06:02 peptides (Fig. 1D). Overall 
the nonamer peptide motif (Fig. 1, E and F) of sC*06:02 was near identical to that of mC*06:02 
with only a small difference in the frequency of arginine at P2 (25% as compared with 41%). These 
minor differences in motif were likely due to the reduced number of peptides obtained from soluble 
HLA-I, resulting from lower levels of soluble HLA-C expression. The peptide repertoire obtained 
from sC*06:02 contained a lower proportion of peptides longer than 14 amino acids and a lower 
number of contaminants. That is, there was a low degree of overlap with the long peptides from 
mC*06:02 (7%) and there was a greater proportion of longer peptides that had expected residues in 
the anchor positions. For example, ∼18% of peptides of 16 amino acids in length had leucine at the 
terminal position. Accordingly, the sC*06:02 provided a means of obtaining a similar peptide 
repertoire as mC*06:02 with a lower proportion of contaminating peptides. 
 
X-ray crystal structures of HLA-C*06:02 
To elucidate the structural basis of HLA-C*06:02-mediated peptide presentation, two HLA-
C*06:02 self-peptides, ARTE (ARTELYRSL of Protein_AATF, UniProtKB Q9NY61) and ARFN 
(ARFNDLRFV of RUNX3, UniProtKB Q13761), were selected from the identified HLA-C*06:02 
peptide repertoire. These peptides were selected for meeting the following criteria: (i) they had 
preferred anchor residues (P2-Arg, P7-Arg, and P9-L/V), (ii) they were consistently identified from 
peptide elutions, and (iii) they allowed for significant yields of refolded HLA-C*06:02. 
Furthermore, we selected the previously identified melanocyte peptide antigen ADAMTSL557–
65 (VRSRR-abu-LRL) (37), where “abu” refers to 2-aminoisobutyric acid, a thiol to methyl-
substituted analogue of cysteine. By removing the thiol group, this analogue enabled successful 
pHLA-I refolding while maintaining T-cell reactivity (data not shown) (47). Refolded HLA-C*06:02 
was purified, crystallized, and the structures determined to 1.74 Å for HLA-C*06:02-ARTE, 2.8 Å 
for HLA-C*06:02-ARFN, and 2.3 Å for HLA-C*06:02-ADAMTSL5 (data collection and 
refinement statistics are summarized in Table 1). The high quality of the data allowed for reliable 
placement of the peptide ligands (Fig. 2, A–D). The ARFN peptide was observed in two 
conformations that differed in their placement of the P7-Arg (discussed below under “The structure 
of HLA-C*06:02-ARFN”) (Fig. 2, B and C). 
 
HLA-C*06:02 adopted the typical MHC class I structure and overall the three crystal 
structures of HLA-C*06:02 were highly similar (r.m.s. deviations of 0.44–0.76 Å over 
residues 1–182). The largest difference was seen in the β1-β2 loop (residues 14–19) of the 
HLA-C*06:02-ADAMTSL5 with a 7.2 Å shift due to differential crystal packing. A modest 
difference was seen at the α2 helical-hinge region (residues 147–155), where a 1.2-Å shift in 
the HLA-C*06:02-ARFN structure was observed due to contacts with the P5 position of the 
peptide (Fig. 2E). Overlay of the peptides reveals a high degree of similarity, with the 
greatest differences occurring in the central residues (P4–P7) (Fig. 2F). Nevertheless, the 
conformation of HLA residues available for interaction with T-cell receptors remain largely 
conserved. 
 
The structure of HLA-C*06:02-ARTE  
Analysis of peptide-ligand binding contacts of the HLA-C*06:02-ARTE structure revealed 
extensive main chain interactions across the length of the peptide ligand to the HLA molecule. 
Furthermore, there were internal peptide interactions between the P6-Tyr and P5-Leu, which served 
to constrain the epitope at these positions (48) (Fig. 3A). Three peptide side chains were observed to 
have anchoring roles (P2, P7, and P9), which are buried within the B-, E-, and F-pockets, 
respectively (Fig. 3A). The P2-Arg formed main chain hydrogen bonds to Tyr7, Glu63, and Lys66, 
whereas its side chain was buried deep within the B-pocket and formed salt bridge interactions to 
Asp9 and a hydrogen bond to Ser24 (Fig. 3, A and B). The P7-Arg was supported via main chain 
interactions to Gln70 and Asn77, whereas the P7-Arg side chain was buried within the E-pocket 
where it formed a salt bridge with Asp9 and cation-π stacking against Trp97 (Fig. 3, A and C). The 
C-terminal P9-Leu anchor of ARTE is bound within the F-pocket where its backbone and terminal 
carboxyl formed hydrogen bonds to Asn77, Lys80, Tyr84, and Thr143 (Fig. 3, A and D). The side 
chain sat in a hydrophobic pocket (Leu81, Tyr123, and Trp147) that helped to stabilize the 
interaction (Fig. 3, A and D). These extensive interactions at the B-, E-, and F-pockets support the 
notion of three anchor sites in HLA-C*06:02 with the salt-bridging interactions at the B- and E-
pockets correlating with the observed preference for arginine anchors at these positions within the 
peptide repertoire studies. 
 
The structure of HLA-C*06:02-ARFN  
Although the overall tertiary structure of HLA-C*06:02-ARFN was similar to that of C*06:02-
ARTE, the ARFN peptide was nonetheless observed in two conformations that differed in the 
orientations of the P7-Arg (Fig. 2, B, C, and F) (discussed below). The ARFN peptide displayed 
internal constraints between P3-Phe and P5-Asp (Fig. 2, B, C, and F). Yet, overall the four ARFN 
peptide copies in the asymmetric unit were highly similar to each other at the P3 and P5 positions 
and to each other and the ARTE structure, detailed above, at the P2 and P9 anchor positions. That 
is, the P2-Arg residues formed backbone contacts to Tyr7, Glu63, and Lys66 and the side chains 
were buried within the B-pocket where they made contacts to the Ser24 and Asp9 residues (Fig. 
4A). The P9-V was buried in the F-pocket and formed equivalent backbone contacts (Asn77, Tyr84, 
and Thr143) and hydrophobic side chain contacts to Leu81, Tyr123, and Trp147 (Fig. 4B). Thus, 
whereas the P7-Arg in ARFN adopted two distinct conformations within the crystal, this was not 
clearly attributable to alterations within the peptide or peptide-binding groove distal to the E pocket. 
One P7-Arg conformation (ARFN-1) was in a conformation similar to that observed in ARTE with 
the side chain forming a salt bridge interaction with Asp9 and cation-π interactions with Trp97 (Fig. 
4C). In the other P7-Arg conformation (ARFN-2) the P7-Arg side chain shifted 5.8 Å and no longer 
formed a salt bridge with Asp9, but instead formed a salt bridge with Asp114 (Fig. 4C). Although 
the conformation of E-pocket residues was conserved within the ARFN structures, there was a 140° 
rotation of Trp97 between ARTE and ARFN (Fig. 4D). Taken together, it is likely that plasticity of 
Trp97 in the E-pocket of HLA-C*06:02 fosters changes in the microenvironment around P7-Arg 
anchors such that they can form alternate salt-bridge partners with Asp9 or Asp114. 
 
X-ray crystal structure HLA-C*06:02 with an analogue of a melanocyte peptide antigen 
(ADAMTSL5) 
To structurally characterize the presentation of the melanocyte peptide antigen ADAMTSL5 
(VRSRRCLRL) by HLA-C*06:02 we refolded HLA-C*06:02 with an ADAMTSL5 analogue 
(VRSRR-abu-LRL) that has aminobutyric acid in place of the P6-Cys. This synthetic analogue of 
cysteine was necessary for successful in vitro refolding of the complex for crystallization. Crystals 
of HLA-C*06:02 in complex with the ADAMTSL5 analogue were obtained and a structure solved 
to 2.3 Å (data collection and refinement statistics are summarized in Table 1). 
 
The X-ray crystal structure revealed very similar interactions for the P2-Arg and P9-Leu as seen in 
structures of both ARTE and ARFN complexes (Fig. 5A). Instead of a P7-Arg, however, the 
ADAMTSL5 had a P7-Leu. Although not a dominant residue preference, P7-Leu was present in ∼4% of nonamers eluted from cellular HLA-C*06:02 molecules. The P7-Leu side chain is buried 
within the E-pocket where it forms hydrophobic interactions with Trp97. Of note, Trp97 adopts a 
conformation distinct to that observed in the ARTE and ARFN structures with a 114° rotation (Fig. 
5B). Thus, whereas there was significant conservation of HLA residue conformations in regions 
that are available to T-cell receptor recognition, there was plasticity of the Trp97 side chain to 
facilitate different conformations and residues within the E-pocket of HLA-C*06:02. 
Structural and sequence similarities of HLA-C allomorphs  
There is currently a relative lack of structural information for HLA-C with only 5 allomorphs 
available in the PDB, C*08:01 (49), C*04:01 (50), C*05:01 (51), C*07:02 (51), and C*03:04 (52). 
Comparison of our highest resolution HLA-C*06:02 structure (ARTE) to the other currently 
available HLA-C structures revealed a high degree of similarity of the peptide-binding grooves with 
r.m.s. deviations over residues 1–182 of 0.75 Å to HLA-C*08:01 (4NT6), 0.71 Å to C*03:04 
(1EFX), 0.97 Å to C*05:01, 0.68 Å to C*07:02 and 0.81 Å to C*04:01 (1QQD). Comparison of 
HLA-C*06:02-ARTE to HLA-B27:05, an allomorph that also has a preference for peptides with a 
P2-Arg (42), also showed a high degree of similarity in the peptide-binding groove, with an r.m.s. 
deviation of 0.63 (Fig. 6A). 
 
The surface electrostatics of HLA-C*06:02 reveals a primarily negative charge across the peptide-
binding groove, especially in the B- and E-pockets (Fig. 6B). By contrast, the other available HLA-
C structures have more positively charged peptide-binding grooves (Fig. 6, A–G). HLA-C*04:01 
has a highly positive B-pocket and small area of negative charge in the E-pocket (Fig. 6C), whereas 
C*03:04 has a similarly negatively charged E-pocket, yet a relatively uncharged B-pocket (Fig. 
6D), and in contrast HLA-C*05:01 and HLA-C*08:01 have mostly positively charged B- and E-
pockets (Fig. 6, Eand F). On the other hand HLA-C*07:02 and HLA-B*27:05, both allomorphs 
that have a preference for peptides with a P2-Arg (42, 51), also display a high degree of negative 
charges across the entire peptide-binding groove (Fig. 6, G and H).  Analysis of the peptide-
binding pocket volume with the CASTp server (53) shows HLA-C*06:02-ARTE has a much larger 
binding pocket than the other available HLA-C structures. HLA-C*06:02 has a pocket volume of 
1900 Å3, whereas the other available HLA-C structures range between 1600 and 1800 Å3. This 
large volume for HLA-C*06:02 is attributable to the deep B- and E-binding pockets. 
 
HLA-C*04:01 is a relatively well-understood HLA-C allomorph with a previously published 
peptide repertoire and a crystal structure available (PDB 1QQD) (19, 50). Accordingly, HLA-
C*04:01 was selected to provide a structural comparison with HLA-C*06:02. A sequence 
alignment of the B- and E-pockets of some of the common HLA-C allomorphs reveals that most of 
the HLA-C allomorphs lack the necessary residues for positively charged anchor residues at P2 and 
P7 (Fig. 7A). In the B-pocket, the majority of the HLA-C allomorphs lack the negatively charged 
Asp9 that attracts positively charged P2 anchor residues. Indeed, the only allomorphs that have a 
Asp9 are the HLA-Cw6 and HLA-Cw7 allomorphs that have similarly been shown to present 
peptides with P2-Arg (18). From a structural perspective, the allomorphic differences in HLA-
C*04:01 are evident. Namely, HLA-C*04:01 lacks the necessary negatively charged B-pocket and 
instead has a B-pocket with small uncharged residues (Ser9 and Ala24) and has a preference for 
large hydrophobic residues such as phenylalanine or tyrosine (Fig. 7, B and C). In the E-pocket, 
positions 114 and 97 are dimorphic (Asn to Asp and Arg to Trp, respectively) so that they are 
unlikely to prefer positively charged P7 anchor residues (Fig. 7A). For example, in HLA-C*04:01, 
residues 97 and 156 are Arg (as opposed to Trp in C*06:02), and thus would repel positively 
charged peptide residues (Fig. 7, D and E). In the F-pocket, the majority of pocket residues are 
conserved and therefore they are likely to have similar hydrophobic residue terminal anchor 
preferences (Fig. 7, A, F, and G). Interestingly, the only other common HLA-C allomorph with an 
E-pocket strictly conserved with HLA-C*06:02 is C*12:03, which has tentative associations with 
psoriasis and psoriasis arthritis (54, 55). Accordingly, HLA-C*06:02 has a unique peptide-binding 
groove with very negatively charged B- and E-pockets, making it well-suited to bind peptides 
containing large positive charged residues at the P2 and P7 positions, and thus selects a unique 
repertoire of peptides. 
 
 
DISCUSSION  
The HLA-C*06:02 peptide repertoire data provides important new insights into determinant 
selection by this molecule. For instance, HLA-C*06:02 peptides have been previously eluted from 
cancer cell lines in the presence of other HLA allomorphs (41), whereas another study utilized non-
native peptide libraries as a general approach for studying HLA-C peptide motifs including 
C*06:02 (18). These studies are in general agreement with our findings that HLA-C*06:02 prefers 
nonamer peptides and has strong preferences for Arg and Leu at P2 and PΩ, respectively. By 
contrast, the preference for the P7-arginine, although observed in previous studies occurred at a low 
frequency (18, 41). Our data suggests that the P7-arginine occurs at similar frequencies to the P2-
arginine and is likely an equally dominant anchor residue. This discrepancy is likely due to the 
improved robustness of our dataset imparted by the elution of a larger number of peptides and the 
elution of naturally presented self-peptides. The presence of longer peptides (14–18-mers) in our 
dataset was unexpected. As we have accounted for common HLA-II-associated contaminants, and 
the longer peptides do not conform to the motif we defined for HLA-C*06:02, we suspect these 
longer peptides are contaminants from other cellular sources. Yet, we cannot rule out that there may 
be bona fide epitopes within this longer subset. 
 
The preference for Arg at P2 and P7 appears to be a unique feature, among the common HLA-C 
alleles, of HLA-C*06:02. Peptide repertoire analysis allowed us to identify peptides with optimal 
anchor residues for HLA-C*06:02. From these peptides we identified ARTE (ARTELYRSL, 
UniProtKB Q9NY61) and ARFN (ARFNDLRFV of RUNX3, UniProtKB Q13761) for which we 
were able to determine structures bound to HLA-C*06:02. In line with the peptide repertoire data, 
these structures reveal that HLA-C*06:02 has two deep electronegative pockets that prefer the 
accommodation of P2- and P7-arginine residues. The E-pocket of HLA-C*06:02 has a mobile 
Trp97 residue, which allows for multiple orientations of the P7-Arg of the presented peptides. From 
sequence alignments and previous repertoire data (18) it can be seen that other HLA-C allomorphs 
have Arg preferences at P2 or P7, but no other common allotype has both. For example, the HLA-
Cw7 group has preference for P2-Arg containing peptides and HLA-C*12:03 likely has a 
preference for an Arg at P7 (18). This preference for a P7-Arg coincides with a tentative association 
of HLA-C*12:03 with psoriasis (54). Thus, HLA-C*06:02 has a uniquely negatively charged 
antigen-binding cleft that inclines the molecule to the presentation of a distinct repertoire of 
positively charged peptides. 
 
Using this repertoire-determined motif we are able to predict the ability of putative peptide antigens 
to be presented by HLA-C*06:02. To date, a number of putative HLA-C*06:02-restricted psoriasis 
peptide antigens have been identified, including peptides from: streptococcus M protein, human 
keratin, the antimicrobial LL-37 and recently a peptide antigen from melanocytes. We can collate 
the current putative HLA-C*06:02-restricted peptide antigens and rank their potential to be 
presented by HLA-C*06:02 (Table 2). Based on these predictions the streptococcus M6 peptides 
282M6–9 and 324M6–9 have a high likelihood of being presented by HLA-C*06:02 because both 
of these peptides have the preferred P2- and P7-Arg residues and the terminal P9-Leu (56). Most of 
the identified Keratin17 peptides will likely have low association with HLA-C*06:02 with the 
exception of 217K17–9, which has the preferred P7-Arg and P9-Leu. Similarly, for the LL-37 
peptides identified most are predicted to associate poorly with HLA-C*06:02 with the exception of 
the LL37p6s and LL37p5s peptides (36) (Table 2). Indeed, of the LL-37 epitopes predicted by in 
silico methods to bind HLA-C*06:02 we were only able to successfully refold LL37p6s and 
LL37p5s (data not shown). Accordingly, this structurally-informed peptide repertoire analysis 
provides a template to rank the affinity of putative psoriatic autoantigens for HLA-C*06:02. 
 
The HLA-C*06:02–VRSRR-abu-LRL structure suggests that the mimotopes identified by 
Arakawa et al. (37) share a common positively charged solvent-accessible surface for docking of the 
Vα3S1/Vβ13S1 TCR. The Vα3S1/Vβ13S1 TCR was previously identified from a CD8+ T-cell 
clone isolated from the epidermis of lesional skin tissue of a HLA-C*06:02-positive psoriasis 
patient (37, 57). A preference for Vβ13.1 gene usage has been seen previously in epidermal psoriatic 
CD8+ T-cells (58, 59). As the VRSRR-abu-LRL peptide had canonical P2-Arg and P9-Leu anchors 
with the leucine in the P7 position accommodated by reorientation of the Trp97, the trio of arginine 
residues at P4, P5, and P8 are solvent exposed. This trio of arginines is highly conserved in 
mimotopes recognized by the Vα3S1/Vβ13S1 TCR, suggesting it is the positively charged surface 
of the epitope that promotes TCR recognition (37). However, the extent to which the Va3S1/Vb13S1 
TCR and the ADAMTSL5 peptide are a bona fidepsoriatic autoreactive pairing is unknown as the 
trigger(s) of psoriasis remain unclear. Furthermore, the extent to which Vβ13.1 gene usage is a 
general feature of psoriatic TCR repertoires is unknown. Nonetheless, it is tempting to speculate 
that arginine- and lysine-rich epitopes on antimicrobial peptides or bacterial proteins (like 
streptococcal M protein) may elicit HLA-C*06:02 restricted autoreactivity. In conclusion, in 
presenting the peptide repertoire and structural characterization of HLA-C*06:02 we provide a base 
for further rational interrogation of this molecule. 
 
 
EXPERIMENTAL PROCEDURES 
Cell line development and culture 
Full-length HLA-C*06:02 was cloned into the pcDNA3.1 vector and stably transfected into 
the HLA class Ia-deficient cell line 721.221 by antibiotic selection. The full-length HLA-
C*06:02 721.221 cell line (mC*06:02) was cultured in RPMI 1640 supplemented with 10% 
FCS, 1× GlutaMAX (Gibco), and G418 sulfate (50 μg/ml). 
 
HLA-C*06:02 was truncated to create a soluble construct that lacked the transmembrane and 
cytoplasmic regions (residues 1–303). The soluble construct was cloned into the pIRES2-ZsGreen1 
vector and transfected into the 721.221 cell line by Lipofectamine 2000 reagent and standard 
protocols. Cell lines were selected with G418 sulfate antibiotic and sorted by GFP expression levels 
at FlowCore (Monash University). The soluble C*06:02 721.221 cell line (sC*06:02) was cultured 
in CELLine bioreactor flasks (Argos Technologies) with RPMI 1640 media supplemented with 2% 
FCS, 1× GlutaMAX (Gibco), and G418 sulfate (50 μg/ml). 
 
Peptide repertoire by mass spectrometry  
The peptide repertoire of full-length HLA-C*06:02 (mC*06:02) was determined as previously 
described (19). In short, 3 × 109 721.221 cells were lysed by cryogenic grinding in a Mixer Mill 
MM 400 (Retsch) followed by incubation in 50 mM Tris, pH 8.0, 150 mM NaCl, 2.5 mM EDTA, 
0.5% IGEPAL (Sigma) and protease inhibitors (Roche Applied Science) and mC*06:02 was 
purified using the Pan-HLA class I antibody W6/32 immobilized to protein A resin. HLA-protein 
complexes were eluted with 10% acetic acid and peptides were further separated by reverse-phase 
HPLC. Peptides were then analyzed by Q Exactive Hybrid Quadrupole-Orbitrap Mass Spectrometer 
(Thermo Scientific) and identified by database search using the human UniProtKB/SwissProt 
database (Feb 2016) (60) with ProteinPilot version 5.0 (SCIEX). A false discovery rate of 5% was 
applied and a list of known contaminants, including known class II peptide ligands derived from 
this cell line, removed. The peptide repertoire of soluble HLA-C*06:02 (sC*06:02) was determined 
as described for membrane-bound HLA-C*06:02 with the exception that the initial cellular lysis 
steps were omitted and sC*06:02 was immunoaffinity purified directly from the cell culture media. 
A list of identified peptides is shown in supplemental Table S1. 
 
Protein expression and purification 
The extracellular portion of HLA-C*06:02 (residues 1–274) and human β2-microglobulin (β2m) 
were each cloned into the pET30 expression vector system and expressed into inclusion bodies 
within Escherichia coli. Inclusion bodies were harvested and solubilized in 20 mM Tris-HCl, pH 
8.0, 6 M guanidine hydrochloride, 1 mM EDTA, 1 mM DTT, and 0.2 mM PMSF. HLA-C*06:02 
heavy chain was refolded in the presence of human β2m (120 and 30 mg, respectively) and 10 mg 
of the self-peptides ARTE (ARTELYRSL of Protein_AATF, UniProtKB Q9NY61) or ARFN 
(ARFNDLRFV of RUNX3, UniProtKB Q13761) or an analogue of a melanocyte autoantigen 
(VRSRR-abu-LRL of ADAMTSL5, UniProtKB X6R4H8), where an aminobutyric acid residue is 
substituted in place of cysteine in the P6 position (37). Refolds were carried out in 1 liter of refold 
buffer (0.1 M Tris-HCl, pH 8.0, 2 mM EDTA, 0.4 M L-arginine, 0.5 mM oxidized glutathione, 5 
mM reduced glutathione, and 0.2 mM PMSF). The refold solution was then dialyzed into 20 
mM Tris-HCl, pH 8.0. Refolded HLA-C*06:02 was initially purified by weak anion exchange 
(DEAE-Sepharose) followed by size exclusion chromatography on a S200/16/60 column (GE 
Healthcare) in 20 mM Tris, pH 8.0, 150 mM NaCl. The final purification step was anion exchange 
chromatography with a HiTrap Q column with a linear gradient of 20 mM Tris, pH 8.0, 0 to 
1 M NaCl. Samples were buffer exchanged to 20 mM Tris, pH 8.0, 150 mM NaCl for storage prior 
to use. 
Crystallization and X-ray data collection 
Prior to crystallization HLA-C*06:02 was concentrated to 10 mg/ml in a buffer comprised of 10 
mM Tris, pH 8.0, 100 mM NaCl. Crystals of HLA-C*06:02 were grown using the hanging-drop 
vapor diffusion method at 298 K. The HLA-C*06:02-ARTE crystals were grown from a reservoir 
solution of 0.1 M Bis-Tris propane, pH 7.0, 0.1 Msodium fluoride, and 20% PEG 8000. The HLA-
C*06:02-ARFN crystals were grown in 0.1 M Tris, pH 8.5, 0.2 M sodium acetate, and 20% PEG 
3350. HLA-C6*06:02-ADAMTSL5 crystals were grown from a reservoir solution of 0.1 M sodium 
acetate, pH 4.5, and 1.8 M ammonium citrate. Crystals were equilibrated in reservoir solution with 
the addition of 15% sucrose for HLA-C*06:02-ARTE and 30% PEG 3350 for HLA-C*06:02-
ARFN and 15% ethylene glycol for HLA-C*06:02-ADAMTSL5 prior to flash cooling in liquid 
nitrogen for data collection. X-ray diffraction were collected at 100 K at the MX2 beamline of the 
Australian Synchrotron. 
 
Structure determination and refinement 
X-ray crystal images were processed with XDS (61) and then scaled and merged with AIMLESS (62). 
For HLA-C*06:02-ARTE initial phases were solved by molecular replacement using PHASER (63) 
with HLA-C*08:01 used as the initial search model (PDB 4NT6) (49). An initial round of rigid body 
refinement was carried out with REFMAC5 (64), followed by rounds of restrained refinement in 
REFMAC5 and model building with COOT (65). Solvent was added with ARP/wARP (66). 
Translational liberation screw rotation (TLS) refinement was applied to the final rounds of 
refinement in REFMAC.   Initial phases of HLA-C*06:02-ARFN were solved using PHASER with 
HLA-C*06:02-ARTE (excluding the peptide ligand) as the initial search model. Repeated rounds of 
refinement were carried out with BUSTER (67) and model building with COOT. NCS restraints were 
applied and TLS refinement was applied in final rounds of refinement. 
 
Initial phases of HLA-C*06:02-ADAMTLS5 were also determined using HLA-C*06:02-ARTE 
without the peptide ligand as the search model as implemented in PHASER. Iterative rounds of 
refinement were carried out with PHENIX (68) and model building with COOT. A single round of 
simulated annealing was performed to minimize bias and TLS was applied to final rounds of 
refinement. 
 
HLA-C*06:02-ARTE was solved in the P21 space group and refined to a resolution of 1.74 Å. The 
final structure contained two HLA-C*06:02 protein complexes in the asymmetric unit with each 
comprising residues 2–274 of HLA-C*06:02 heavy chain and the full-length β2m (1–99) as well as 
an additional N-terminal start methionine (M0). The entire ARTE peptide (ARTELYRSL) was 
visible for both complexes and unambiguously built. 
 
HLA-C*06:02-ARFN was solved in the P212121 space group at 2.8-Å resolution. The structure 
contained four HLA-C*06:02 protein complexes in the asymmetric unit. Three HLA-C*06:02 
protein complexes were comprised of residues 2–274 for the heavy chain, with one chain lacking 
residues 104–108 of the α2S1-S2 loop. All protein complexes comprised full-length β2m (0–99) 
and had unambiguous density for the ARFN peptide (ARFNDLRFV). 
 
HLA-C*06:02-ADAMTSL5 was also solved in the P212121 space group to a resolution of 2.3 Å 
and contained one HLA-C*06:02 protein complex in the asymmetric unit. The protein complex 
comprised residues 2–274 for the heavy chain and residues 1–99 for β2m. The peptide ligand 
(VRSRR-abu-LRL) had clear density for all side chain atoms with the exception of the P4-Arg, 
which had insufficient density beyond atom Cδ. The P6 aminobutyric acid residue was built using 
ABA from the CCP4 monomer library. Data collection and refinement statistics for all structures 
are summarized in Table 1. 
 
 
 
Abbreviations used: 
HLA   human leukocyte antigen 
KIR   Killer-cell immunoglobulin-like receptors 
ARTE   ARTELYRSL 
r.m.s.   root mean square 
PSORS1   psoriasis susceptibility locus 1 
β2m   β2-microglobulin 
abu   aminobutyric acid 
Bis-Tris propane  1,3-bis[tris(hydroxymethyl)methylamino]propane 
TLS   translational liberation screw rotation 
PDB   Protein Data Bank. 
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Table 1 - X-ray diffraction data collection and refinement statistics  
 
 
 
 
 
 
  
Table 2 - Putative HLA-C*06:02 restricted psoriasis peptide antigens - A list of putative 
HLAC*06:02 restricted peptide antigens obtained from literature. Table contains peptide 
sequences and residues at HLA-C*06:02 anchor positions. A bind score ranging from one (*) to six 
(*) depending on each anchor residue. Six (*) denotes a peptide that has all favoured residues in the 
anchor residues and a (-) denotes all unfavourable residues. 
 
 
  
Figure legends  
 
Figure 1 - Analysis of peptides eluted from HLA-C*06:02.  
(A) Length distribution of HLA-C*06:02 presented peptides. (B) Peptide preference motif obtained for 
peptide nonamers for membrane bound HLA-C*06:02. Dominant, Strong and Preferred amino acids occur 
at frequencies of >30%, >20% and >10% respectively. (C) Sequence Logo of nonomer peptides of membrane 
bound HLA-C*06:02. Enriched amino acids are shown above and depleted are shown below. Height of 
amino acids are proportional to frequency of occurrence. Sequence Logos were generated with 
Seq2Logo server as a p-weighted Kullback-Leibler logo. (D) Overlap of peptide nonamers from 
membrane bound and soluble HLA-C*06:02. (E) Peptide preference motif obtained for peptide 
nonamers from soluble HLA-C*06:02. (F) Sequence Logo of nonomer peptides of soluble HLA-C*06:02.  
 
Figure 2 - Overall structures of the peptide-binding grooves of HLA-C*06:02-ARTE, ARFN and 
ADAMTSL5.  
The a2 helix has been removed for clarity. In grey is the simulated annealing FO-FC omit electron density 
surrounding the peptide ligands, contoured at 3 s. (A) The HLA-C*06:02 peptide-binding groove represented 
as cartoon (teal) with the ARTE peptide as sticks (yellow). (B-C) The ARFN peptide was observed in two 
conformations in the asymmetric unit. (B) The ARFN-1 confirmation with the HLA represented as cartoon 
(blue) and the peptide as sticks (green). (C) The ARFN-2 conformation with the HLA represented as cartoon 
(lime green) and the peptide as sticks (blue). (D) The ADAMTSL5 peptide. The HLA is represented as cartoon 
(green) and the peptide as sticks (wheat). (E) Overlay of Ca traces of HLA-C*06:02 structures. The regions of 
difference at the b1-b2 loop and a2 helical hinge are labelled. (F) Overlay of the HLA-C*06:02 peptide ligands.  
 
Figure 3 - Structure of HLA-C*06:02-ARTE. (A) The ARTE peptide within HLA-C*06:02 peptide 
binding groove.  
Residues 1 - 126 of the HLA are represented as cartoon (teal) and the ARTE peptide is shown as yellow 
sticks. The pockets of the peptide binding groove are represented as grey discs and labelled A-F. (B) The B 
pocket of HLA-C*06:02. Contacts between the P2 arginine anchor (yellow sticks) and side chains of HLA-
C*06:02 residues (orange sticks). (C) The E pocket of HLA- C*06:02. Contacts between the P7 arginine anchor 
(yellow sticks) and side chains of HLA-C*06:02 residues (orange sticks). (D) The F pocket of HLA-
C*06:02. Contacts between the P leucine anchor (yellow sticks) and side chains of HLA-C*06:02 (orange 
sticks).  
 
Figure 4 - Comparison of the two conformations of ARFN peptide observed in the crystal structure.  
First conformation of ARFN (ARFN-1) represented as sticks (green) with the HLA represented as cartoon 
(grey) with HLA sidechains contacting the peptide shown as sticks (pink). The second conformation of the 
ARFN (ARFN-2) peptide is represented as sticks (blue) the HLA represented as cartoon (grey) with HLA 
sidechains contacting the peptide shown as sticks (pink).  (A) Conservation of contacts between the HLA and 
the ARFN-1 and ARFN-2 peptides at the P2-Arg position. (B) Conservation of contacts between the HLA and 
the ARFN-1 and ARFN-2 peptides at the P -Val position. (C) The ARFN-1 and ARFN-2 conformations differ in 
the orientation of their P7-Arg side chain. The P7-Arg of ARFN-1 forms a salt-bridge with Asp9 whereas the P7-
Arg of ARFN-2 is shifted 5.8 Å and forms a salt-bridge with Asp114. (D) Plasticity of Trp97 was observed 
between the HLA-C*06:02-ARTE and ARFN structures. The ARTE, ARFN-1 and ARFN-2 peptides are 
shown as yellow, green and blue sticks respectively. The Trp97 observed in the ARTE complex (orange 
sticks) is rotated 140° compared to the Trp97 of the ARFN complex (pink sticks).  
Figure 5 - Structure of HLA-C*06:02-ADAM peptide analogue (VRSRR-abu-LRL).  
(A) View of ADAMTSL5 peptide analogue (VRSRR-abu-LRL) within the HLA-C*06:02 peptide binding 
-C*06:02 residues 1 - 126 are represente cartoon 
(green) with sidechains within 3.4 Å represented as sticks (blue). The ADAMTSL5 peptide is represented 
sticks (wheat). (B) Overlay of P7-Arg of HLA-C*06:02-ARTE, represented as sticks (grey), with the P7-
Leu of ADAMTSL5 represented as sticks (wheat). Plasticity of Trp97 was observed between the HLA-
C*06:02-ARTE and the ADAMTSL5 structure. The ARTE peptide is coloured grey, the ADAMSTL5 
peptide is coloured wheat. The Trp97 observed in the ARTE complex (orange sticks) is rotated 114° compared 
to the Trp97 of the ADAMSTL5 complex (blue sticks).  
 
Figure 6 - Comparison of available HLA-C structures.  
(A) Ca trace overlay of HLA-C*06:02 (teal), HLA-C*03:04 (PDB: 1EFX) (green), HLA-C*04:01 (PDB: 
1QQD) (pink), HLA-C*05:01 (PDB: 5VGD) (purple), HLA-C*07:02 (PDB: 5VGE) (yellow), HLA-C*08:01 
(PDB: 4NT6) (wheat) and HLA-B*27:05 (PDB: 3BP4) (blue). Surface electrostatics of (B) HLA-C*06:02 
ARTE (C) HLA-C*04:01, (D) HLA-C*03:04 (E) HLA-C*05:01, (F) HLA-C*08:01 (G) HLA-C*07:02 and (H) 
HLA-B*27:05. B and E-pockets are shown as yellow circles. Generated using APBS Tools plugin within 
PyMOL.  
 
Figure 7 - A comparison of the anchor pockets of HLA-C*06:02 with other HLA-C alleles.  
(A) Sequence alignment of the B-, E- and F-pockets of common HLA-C molecules. Residues conserved with 
HLA- C*06:02 are shown as a dash (-). (B - G) A structural comparison of the anchor pockets of HLA-C*06:02 
and HLA-C*04:01 (PDB: 1QQD). The HLA-C*06:02-ARTE peptide is represented as yellow sticks. The 
alternate conformation of the P7- Arg of the ARFN peptide is shown as blue sticks. The HLA-C*06:02 pocket 
residues are shown as teal sticks and van de Waals surface (VDW). The HLA-C*04:01 peptide represented 
as pink sticks. The HLA-C*04:01 pocket residues are shown as purple sticks and VDW surface. Panels (B 
and C) The B pocket. Panels (D and E) The E pocket. Panels (F and G) The F pocket.  
 
  
  
 
 
 
 
  
  
 
 
 
 
 
  
  
 
 
 
 
  
  
 
 
 
 
  
  
 
 
 
 
  
  
 
 
 
 
 
  
  
 
 
